Structure Therapeutics saw a boost in stock price after positive phase 2 data for aleniglipron in 2025. The weight loss medicine showed competitive results in clinical trials, with a potential entry into the anti-obesity market. However, competition is fierce, and any setbacks could lead to a significant decline in shares. The company plans to initiate a phase 3 study for aleniglipron, but faces challenges in a crowded market with other oral weight loss medicines already approved or in development. Investors should weigh the risks and rewards carefully before considering investing in Structure Therapeutics.

Read more at Yahoo Finance: Can This Stock Double Again in 2026?